Skip to main content

Table 1 Echocardiographic assessment of left ventricle functions in mice

From: FNDC5 attenuates obesity-induced cardiac hypertrophy by inactivating JAK2/STAT3-associated inflammation and oxidative stress

 

Ctrl-WT

Ctrl-FNDC5−/−

HFD-WT

HFD-FNDC5−/−

IVSd (mm)

0.7 ± 0.02

0.74 ± 0.02

0.75 ± 0.01†

0.82 ± 0.02*†

IVSs (mm)

1.07 ± 0.02

1.1 ± 0.03

1.19 ± 0.02†

1.20 ± 0.02†

LVIDd (mm)

4.05 ± 0.11

4.0 ± 0.11

3.98 ± 0.14

4.01 ± 0.1

LVIDs (mm)

3.16 ± 0.13

2.98 ± 0.1

2.73 ± 0.12†

2.84 ± 0.08

LVPWd (mm)

0.72 ± 0.02

0.74 ± 0.03

0.77 ± 0.02

0.85 ± 0.02*†

LVPWs (mm)

1.17 ± 0.02

1.18 ± 0.03

1.25 ± 0.02†

1.24 ± 0.03

LVEF (%)

59.4 ± 2

57.3 ± 1.6

48.1 ± 1.7†

49.7 ± 1.7†

LVFS (%)

32.2 ± 1.3

30.3 ± 1.2

25.2 ± 1.2†

24.7 ± 1.5†

  1. IVSs and IVSd interventricular septum at end systole and diastole, LVIDs and LVIDd left ventricular internal dimensions at end systole and diastole, LVPWs and LVPWd left ventricular posterior wall dimensions at end systole and diastole, LVEF left ventricular ejection fraction, LVFS left ventricular fractional shorting
  2. Values are mean ± SEM. *P < 0.05 vs. WT. †P < 0.05 vs. Ctrl. n = 6